Background Schizophrenia is a common, severe, and usually chronic disorder. Maintenance
treatment with antipsychotic drugs can prevent relapse but also causes side-effects. We …

The usefulness of current psychiatric classification, which is based on ICD/DSM categorical
diagnoses, remains questionable. A promising alternative has been put forward as the …

According to current evidence and guidelines, continued antipsychotic treatment is key for
preventing relapse in people with schizophrenia‐spectrum disorders, but evidence‐based …

Cognitive dysfunction is a well-established feature of schizophrenia, and there is evidence
suggesting that cognitive deficits are secondary to abnormal neurodevelopment leading to …

Cognitive deficits are a core aspect of psychotic disorders; however, it is not clear to which
extent different pharmacological treatments could distinctly impact these outcomes. Hence …

Originally published in February 2004. This guideline is more than 5 years old and has not
yet been updated to ensure that it reflects current knowledge and practice. In accordance …

Objective: Schizophrenia is associated with a marked cognitive impairment that is widely
believed to remain stable after illness onset. Yet, to date, 10-year prospective studies of …

Context Neurocognitive impairment in schizophrenia is severe and is an important predictor
of functional outcome. The relative effect of the second-generation (atypical) antipsychotic …

Tardive dyskinesia (TD) risk with D2/serotonin receptor antagonists or D2 receptor partial
agonists (second‐generation antipsychotics, SGAs) is considered significantly lower than …

The treatment of schizophrenia has evolved over the past half century primarily in the
context of antipsychotic drug development. Although there has been significant progress …